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Abstract
AIM: To evaluate the clinical relevance of each cofactor 
on clinical presentation of chronic hepatitis B.
METHODS: Out of 1366 hepatitis B surface antigen 
(HBsAg) positive subjects consecutively observed in 79 
Italian hospitals, 53 (4.3%) showed as the only cofac-
tor hepatitis D virus (HDV) infection [hepatitis B virus 
(HBV)/HDV group], 130 (9.5%) hepatitis C virus (HCV) 
(group HBV/HCV), 6 (0.4%) human immunodeficiency 
virus (HIV) (group HBV/HIV), 138 (10.2%) alcohol 
abuse (group HBV/alcohol); 109 (8.0%) subjects had 
at least two cofactors and 924 were in the cofactor-free 
(CF) group.
RESULTS: Compared with patients in group CF those 
in group HBV/alcohol were older and more frequently 
had cirrhosis (P  < 0.001), those in group HBV/HDV 
were younger (P  < 0.001), more frequently resided in 
the south of the country and had cirrhosis (P  <0.001), 
those in group HBV/HCV were older (P  < 0.001) and 
more frequently had cirrhosis (P  < 0.001). These cofac-
tors were all independent predictors of liver cirrhosis in 
HBsAg positive patients. Multivariate analysis showed 
that an older age [odds ratio (OR) 1.06, 95% CI: 
1.05-1.08], alcohol abuse with more than 8 drinks daily 
(OR 2.89, 95% CI: 1.81-4.62) and anti-HDV positivity 
(OR 3.48, 95% CI: 2.16-5.58) are all independently as-
sociated with liver cirrhosis. This association was found 
also for anti-HCV positivity in univariate analysis, but it 
was no longer associated (OR 1.23, 95% CI: 0.84-1.80) 
at multivariate analysis.
CONCLUSION: Older age, HDV infection and alcohol 
abuse are the major determinants of severe liver dis-
ease in chronic HBV infection, while HCV replication 
plays a lesser role in the severity of hepatic damage.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Seroepidemiological studies on the aetiology of  chronic 
hepatitis in Italy performed in the 1980s, 1990s[1-3] and in 
2001[4] showed a progressive reduction in the prevalence 
of  hepatitis B surface antigen (HBsAg) positive cases 
from 60.7% observed in cases collected from 1976 to 
1981[1] to 13% found in 2001[4]. Despite this, infection by 
the hepatitis B virus (HBV) is still responsible for a siz-
able number of  cases of  chronic hepatitis and/or hepa-
tocellular carcinoma (HCC), and the burden of  HBV 
infection on the healthcare system in Italy is still heavy.
In a multicentre study carried out on 1829 patients 
with cirrhosis in 1992, the prevalence of  HBV-related 
cases was 13.8%; in particular, HBV was the only aetio-
logical factor in 4.2% of  cases, most cases being associ-
ated with cofactors (9.6%): hepatitis D virus (HDV) in 
3.4%, hepatitis C virus (HCV) in 3.2% and alcohol abuse 
in the remaining 3%[5]. In human immunodeficiency virus 
(HIV)/HBV dual infection, found in 3.7%-4.6% of  HIV 
positive subjects in Italy but estimated around 10% in 
people with HIV infection worldwide[6], the prevalence of  
patients with cirrhosis is reported as higher than in HIV-
negative/HBV-positive cases[7]. Cofactors may therefore 
play a substantial role in the progression of  HBsAg posi-
tive chronic hepatitis to the more severe clinical forms[8-10].
The gradual reduction in the percentage of  HBsAg 
positive cases was associated with a dramatic decrease 
in the prevalence of  cases with HBV/HDV dual infec-
tion[11-13]. About a quarter of  HBsAg positive patients with 
chronic hepatitis were anti-HDV positive in 1978-1981[14] 
and in 1987[15]; this prevalence was lower in 1992 (14.4%)[16], 
in 1997 (8.3%)[17] and in 2001 (9.9%)[4]. No data to this ef-
fect are available on HBV/HCV dual infection and on the 
association of  HBV infection/alcohol intake[18].
Our survey on the largest series of  patients with 
chronic hepatitis ever studied in Italy showed an overall 
low HDV prevalence in HBsAg chronic carriers (9%), a 
high prevalence of  patients with HBV/HCV dual infec-
tion (16.9%) and alcohol abuse (10.4%)[4]. The data from 
this study allow us to evaluate the current main character-
istics of  patients with HBV/HDV or HBV/HCV chron-
ic infection or HBV infection/alcohol abuse compared 
with a large control group of  HBsAg chronic carriers 
with no evident cofactor. 
MATERIALS AND METHODS
The study design was more extensively described in a 
previous paper[4]. Seventy-nine centres participated in 
the study, 25 in the North, 24 in the Centre and 30 in 
the South of  Italy and the two main islands (Sicily and 
Sardinia).
All subjects consecutively referred from February 1 
to July 31, 2001 as in-patients or out-patients to one of  
the 79 Italian centres were recruited; 9997 patients with 
chronic hepatitis were enrolled. Both tertiary and pe-
ripheral centres were randomly selected by a systematic 
cluster sampling procedure. For each of  these three geo-
graphical areas, all of  the hospitals were identified and 
listed numerically according to an assigned number. In 
each list, a single hospital was considered as a cluster. The 
first cluster was randomly chosen, whereas the others 
were selected with a probability proportional to the re-
quired number of  hospitals at systematic intervals. Both 
prevalent and incident cases were recruited. We defined 
as “incident cases” all new diagnoses of  chronic liver dis-
ease made during the enrolment period, and as “prevalent 
cases” all subjects with a previous diagnosis of  chronic 
liver disease observed during the study period.
For each subject, the demographic, clinical and aetio-
logical data were recorded using a pre-coded question-
naire. The amount of  alcohol intake was determined 
using a standard questionnaire containing information on 
the daily intake of  various alcoholic beverages and life-
time duration of  alcohol consumption. An alcohol intake 
of  more than 40 g daily for males and 30 g daily for fe-
males for at least 10 years was considered as an aetiologi-
cal cofactor[19,20].
HBV serum markers, HBsAg, anti-HBc, hepatitis B e 
antigen (HBeAg), anti-HBeAg and anti-HDV were deter-
mined by commercial immunoenzymatic assays. Antibod-
ies to HCV were detected by 3rd generation commercial 
immunoenzymatic assays. Antibodies to HIV 1 and 2 were 
determined by commercial enzyme-linked immunosorbent 
assay (Diasorin Biomedica, Saluggia, Vercelli, Italy; Ab-
bott Labs, North Chicago, Illinois, United States) and the 
positive results were confirmed by a Western Blot analysis 
(Genelabs Diagnostics, Science Park Drive, Singapore). 
Patients were enrolled in 2001 when various methods of  
different sensitivity were used to detect HBV viral load in 
different centres in Italy. For this reason, we preferred not 
to evaluate the predicting value of  HBV viral load; data on 
HBV-DNA were given as positive or negative.
Data on HDV-RNA and HDV-Ag were not available. 
We classified patients as asymptomatic carriers when 
alanine aminotransferase (ALT) values were persistently 
normal in the absence of  clinical, biochemical and ultra-
sound signs of  chronic liver disease. Chronic hepatitis 
was diagnosed only on the basis of  liver histology. Liver 
cirrhosis was diagnosed from a liver biopsy or the pres-
ence of  unequivocal clinical, biochemical and ultrasound 
signs[20]. HCC diagnosis was based on histology, imaging 
techniques or biochemical parameters (α1-feto protein 
greater than 400 ng/mL)[21,22]. Patients with serum mark-
ers suggesting autoimmune liver disease and those with 
liver disease associated with genetic disorders were ex-
cluded from the study.
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Statistical analysis
Continuous variables were summarised as mean ± SD 
or median and interquartile range, and categorical vari-
ables as absolute and relative frequencies. Differences in 
the means were evaluated by an unpaired Student t test 
or Kruskal-Wallis one-way analysis of  variance, and the 
χ 2 test was applied to categorical variables. Crude odds 
ratios (OR) and their 95% CI for the association of  
liver cirrhosis with potential risk factors were calculated 
by univariate analysis. Adjusted OR were calculated by 
stepwise logistic regression analysis to identify factors 
independently associated with liver cirrhosis. Only factors 
associated with liver cirrhosis by univariate analysis were 
included in the logistic regression analysis. In the logistic 
model liver cirrhosis was the outcome variable, while age, 
sex, anti-HDV, anti-HCV, alcohol intake, and body mass 
index were the independent variables.
RESULTS
Of  the 1366 HBsAg positive patients, 924 (67.6%) lacked 
all the cofactors investigated (HDV, HCV, HIV and alco-
hol abuse); this group of  patients was named the cofac-
tor-free (CF) group. Fifty-nine (4.3%) patients showed 
HDV infection (anti-HDV positive) as the only cofactor 
(group HBV/HDV), 130 (9.5%) HCV infection (group 
HBV/HCV), 6 (0.4%) HIV infection (group HBV/HIV), 
138 (10.2%) alcohol abuse (group HBV/alcohol) and 
109 (8.0%) had more than one cofactor (group with two 
or more cofactors). Overall, 333 (24.4%) patients had no 
liver biopsy at presentation; of  the remaining 1033 cases, 
278 subjects (26.9%) were classified as asymptomatic 
carriers, 453 (43.9%) as having chronic hepatitis, 249 
(24.9%) as having liver cirrhosis and 53 (5.1%) patients 
had a diagnosis of  HCC. Interferon treatment was given 
in 365 (26.7%) patients and 244 (17.9%) patients received 
Lamivudine. Excluding cases under immunosuppressive 
therapy, approximately all HBeAg positive and half  of  
HBeAg negative cases showed active HBV replication. 
Fifty-seven (4.2%) patients were born outside Italy, and 
only 4 of  them were born in China.
Characteristics of the CF group
The 924 HBsAg positive subjects with none of  the cofac-
tors investigated were more frequently males (66.5%) and 
observed as out-patients (81.1%) and as prevalent cases 
(83.2%); they aged 48.1 ± 14.3 years, were infrequently 
HBeAg positive (12.6%) and frequently showed a mild 
clinical presentation: 26.9% of  cases were asymptomatic 
carriers, 56.9% of  patients showed chronic hepatitis, 
12.4% liver cirrhosis and 3.8% had HCC.
Comparison according to anti-HDV status
The 59 anti-HDV positive patients were younger than 
those in group CF (46.7 ± 11.8 years vs 48.1 ± 14.3 years; 
P < 0.001) and showed higher ALT levels (128 ± 116 IU/L 
vs 98 ± 290 IU/L, P = 0.008); they were more frequently 
observed as in-patients (25.4% vs 18.9%, P = 0.3), were 
more frequently born in southern Italy or on one of  the 
two main islands (67.8% vs 52.9%, P = 0.029) and more 
frequently had liver cirrhosis (37.3% vs 12.4%, P ≤ 
0.001); none of  the 59 anti-Delta positive patients had 
HCC (Table 1).
Comparison according to anti-HCV status
The 130 subjects co-infected with HCV were older than 
those in group CF (55.2 ± 14.7 years vs 48.1 ± 14.3 years, 
P < 0.0001), and more frequently showed liver cirrhosis 
(23.1% vs 12.4%, P < 0.001); this group contained the 
highest prevalence of  patients with HCC observed in the 
study (6.2%) (Table 1). Active HCV replication as evalu-
ated by positive HCV-RNA by RT-PCR was found in 115 
subjects (88.5%). 
Comparison according to anti-HIV status
Only 6 patients showed HBV/HIV dual infection; all 
of  these patients were males and younger than those in 
group CF. Four of  them were HBeAg positive and none 
had liver cirrhosis (Table 1). 
Comparison according to alcohol abuse
Compared with patients in group CF, the 138 HBsAg 
positive patients with alcohol abuse as the only cofactor 
were older (52.6 ± 11.8 years vs 48.1 ± 14.3 years, P < 
0.0001), were more frequently males (92.6% vs 66.5%, P 
< 0.0001), had had fewer years of  schooling (85.9% vs 
67.0%, P < 0.001) and more frequently showed liver cir-
rhosis (31.1% vs 12.4%, P < 0.0001) and HCC (5.1%).
Comparison according to the presence of two or more 
cofactors
Of  the 109 patients in this group, 21 had HBV/HDV/
HCV concurrent infection, 12 HBV/HDV dual infec-
tion plus alcohol abuse, 64 had HBV/HCV dual infec-
tion plus alcohol abuse, and 12 had HBV/HDV/HCV 
concurrent infection plus alcohol abuse. Compared with 
group CF, patients with two or more cofactors were more 
frequently males (86.8% vs 66.5%, P < 0.001), in-patients 
(28.0% vs 18.9%, P = 0.003) and had liver cirrhosis (35.8% 
vs 12.4%, P < 0.001). They more frequently belonged to 
larger families (24.5% vs 14.6%, P < 0.01) and had had 
fewer years of  schooling (84.3% vs 67.0%, P < 0.001). 
Only 4 patients showed HCC (Table 1).
Variables associated with the presence of cirrhosis
At the univariate analysis older age, anti-HCV, HCV-RNA 
positivity, alcohol abuse, anti-HDV and anti-HIV positiv-
ity were all associated with liver cirrhosis. Multivariate 
analysis showed that age (OR 1.10, 95% CI: 1.08-1.11), 
alcohol abuse (between 4 and 8 drinks daily: OR 2.30, 
95% CI: 1.29-4.10; more than 8 drinks daily: OR 2.42, 
95% CI: 1.31-4.46), HDV positivity (OR 2.68, 95% CI: 
1.56-4.61) and anti-HIV (OR 5.78, 95% CI: 1.50-22.27) 
were independent predictors of  the development of  cir-
rhosis, whereas anti-HCV and HCV-RNA positivity were 
no longer associated (Table 2).
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Comparison according to the severity of liver cirrhosis
The Child-Pugh Score was calculated for 229 (92.0%) of  
the 249 patients with cirrhosis: 104 cases in group CF, 43 
cases in group HBV/Alcohol, 19 cases in group HBV/
HDV, 30 cases in group HBV/HCV and 33 cases in the 
HBV/two or more cofactors group. The prevalence of  
patients in the Child-Pugh Classes B or C was lower in 
group CF (31.7%), than in group HBV/Alcohol (44.2%), 
in group HBV/HCV (43.3%) and in the HBV/two or 
more cofactors group (75.8%, P < 0.001) (Table 3).
DISCUSSION
This study is based on three strong points: the first, a 
large sample size, the second, the validity of  the random 
selection including both tertiary and peripheral hospitals 
all over the country, which may have avoided the selec-
tion of  “difficult-to-treat” patients, and lastly, the homo-
geneity of  each single cofactor group and of  the compar-
ative CF group, making this study the first to investigate 
the clinical presentation of  CF HBsAg positive chronic 
hepatitis and the influence of  each single cofactor (HDV, 
HCV and alcohol intake).
Excluding the 442 patients with one or more cofac-
tors enabled us to examine a group of  almost a thousand 
patients with HBsAg positive chronic hepatitis and no 
cofactor. Most of  these patients showed a mild clinical 
presentation and only a minority of  them had liver cir-
rhosis (12.4%), prevalently in the Child A stage. The low 
prevalence of  HCC (3.9%) refers to HCC at the time of  
diagnosis. No information is available on the risk of  oc-
currence of  HCC, death or orthotopic liver transplanta-
tion over time, since the present study is cross-sectional 
and no evaluation of  the clinical outcomes was made.
Despite the decreasing endemicity levels, HDV infec-
tion maintains its geographical distribution in our country, 
i.e., more frequent in southern Italy and on the two main 
islands, as previously described[15-17]. Compared with those 
in group CF, patients in group HBV/HDV showed a 
more severe clinical presentation: they were younger, more 
frequently hospitalised and with evidence of  cirrhosis. In 
accordance with the low prevalence of  patients with HCC 
in previous studies[5], no patient in our HBV/HDV group 
showed HCC, most probably reflecting a more severe 
course of  the illness with a rapid transition to death or to 
the need for liver transplantation before HCC becomes 
evident[23]. On the other hand, patients in group HBV/
HCV were older than those in group CF, more frequently 
had liver cirrhosis and showed an almost double preva-
lence of  HCC. These differences, although not statistically 
significant, may suggest that subjects with long-lasting 
HBV/HCV dual infection are at a higher risk of  develop-
ing liver cirrhosis with or without liver cancer[24-26].
Most patients in group HBV/Alcohol were males 
with a low educational level, a combination more fre-
quently associated with a high risk of  alcohol abuse. 
The prevalence of  patients with cirrhosis was 2.5 times 
higher in group HBV/alcohol than in group CF, a dif-
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Table 1  Comparison of baseline features of hepatitis B surface antigen positive patients, according to different cofactors (mean ± 
SD)  n  (%)
Variable HBsAg positive 
(n  = 924)
HBsAg/anti-HDV 
positive 
(n  = 59)
HBsAg/anti-HCV 
positive 
(n  = 130)
HBsAg/anti-HIV 
positive 
(n = 6)
HBsAg/alcohol 
abuse 
(n  = 138)
HBsAg/two or 
more cofactors 
(n  = 109)
P  value
Age (yr)   48.4 ± 14.0   46.5 ± 11.7   55.2 ± 14.7 37.0 ± 3.6   52.7 ± 11.7   45.8 ± 12.1 < 0.001
Males 606 (66.5) 41 (71.9)   87 (68.0) 6 (100) 126 (92.6) 92 (86.8) < 0.001
In-patients 171 (18.9) 15 (25.4)   29 (22.7) 0   20 (14.7) 30 (28.0)    0.060
Out-patients 732 (81.1) 44 (74.6)   99 (77.3) 6 (100) 116 (85.3) 77 (72.0)
Prevalent cases 769 (83.2) 53 (89.8) 111 (85.4) 6 (100) 115 (83.3) 95 (87.2)    0.500
Incident cases 155 (16.8)   6 (10.2)   19 (14.6) 0   23 (16.7) 14 (12.8)
Born in Italy
   North 192 (21.0) 11 (18.6)   36 (27.7)  3 (50.0)   32 (23.7) 35 (32.4)    0.010
   Centre 195 (21.3) 5 (8.5)   16 (12.3) 0   26 (19.3) 21 (19.4)
   South/islands 484 (52.9) 40 (67.8)   76 (58.5)  2 (33.3)   73 (54.1) 49 (45.4)
   Born Abroad 44 (4.8) 3 (5.1)   2 (1.5)  1 (16.7)   4 (2.9) 3 (2.8)
Asymptomatic carrier 233 (33.5) 3 (6.0)   17 (17.7) 1 (100)   19 (17.6) 5 (6.0) < 0.001
Chronic hepatitis1 313 (45.0) 25 (50.0)   41 (42.7) 0   39 (36.1) 35 (42.2)
Liver cirrhosis 115 (16.5) 22 (44.0)   30 (31.3) 0   43 (39.8) 39 (47.0)
HCC 34 (4.9) 0   8 (8.3) 0   7 (6.5) 4 (4.8)
ALT (× ULN) (median, IQR)      1.0 (1.0-1.8)    2.2 (1.1-4.8)      1.4 (1.0-2.1)   1.5 (1.1-1.8)      1.1 (1.0-2.1)     1.8 (1.0-2.9) < 0.001
BMI (kg/m2) 25.0 ± 3.4 25.5 ± 5.0 24.8 ± 3.1 22.8 ± 2.0 26.1 ± 3.5 25.6 ± 4.1    0.006
Years of schooling < 0.001
   < 6 239 (26.3) 9 (16.4)   46 (36.5)  1 (16.7)   62 (46.3) 31 (28.7)
   6-13 369 (40.7) 31 (56.4)   53 (42.1)  1 (16.7)   53 (39.5) 60 (55.6)
   > 13 299 (33.0) 15 (27.2)   27 (21.4)  4 (66.6)   19 (14.2) 17 (15.7)
HBeAg positive 116 (12.6)   9 (15.3) 10 (7.7)  4 (66.7) 10 (7.2) 15 (13.8) < 0.001
HBeAg negative 808 (87.4) 50 (84.7) 120 (92.3)  2 (33.3) 128 (92.8) 94 (86.2)
1Only subjects with liver biopsy. HBsAg: Hepatitis B surface antigen; HDV: Hepatitis D virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency 
virus; HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; × ULN: Times the upper limit of the normal; IQR: Interquartile range; BMI: Body 
mass index; HBeAg: Hepatitis B e antigen.
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ference most probably due to alcohol intake rather than 
to the association of  the two aetiological factors, since, 
as described in a previous paper[4], 41.8% of  761 patients 
showing alcohol abuse as the only aetiological factor had 
liver cirrhosis. The group of  patients with two or more 
cofactors is a miscellany of  4 subgroups that are too 
small to be analysed or compared with group CF or with 
the other cofactor groups. This miscellaneous group with 
more than one cofactor may be more frequently exposed 
to the aetiological agents of  liver disease and to a higher 
risk of  developing liver cirrhosis and/or HCC.
As observed in previous Italian studies[4,17,18], the major-
ity of  HBsAg positive patients in this study were found 
to be HBeAg negative. Patients with HBV/HCV dual 
infection and those with HBV plus alcohol abuse showed 
a lower prevalence of  HBeAg positive cases than those in 
the other aetiological groups, probably because they were 
older and HBeAg loss is, at least in part, a time-depend-
ent phenomenon.
In conclusion, HBV chronic infection was frequently 
associated with a mild or moderate clinical condition. Liv-
er cirrhosis and HCC were detected in less than one sixth 
of  cases, and viral and metabolic cofactors unfavourably 
influenced the clinical course in patients with chronic 
HBV infection since their presence was associated with 
an increased risk of  cirrhosis, an association proven by 
multivariate logistic regression analysis for HDV infec-
tion and alcohol abuse.
COMMENTS
Background
Many cofactors play a substantial role in the progression of hepatitis B surface 
antigen positive chronic hepatitis to more severe clinical forms.
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Table 2  Risk factors associated with cirrhosis in hepatitis B surface antigen positive patients  n  (%)
Variable Chronic hepatitis Cirrhosis Crude OR (95% CI) Adjusted OR (95% CI) P  value
Age (mean ± SD, yr) 44.9 ± 12.0 56.2 ± 11.6 1.06 (1.05-1.07) 1.10 (1.08-1.11) < 0.001
Gender
   Male 371 (81.9) 192 (77.1) 1
   Female   82 (18.1)   57 (22.9) 1.34 (0.92-1.97)
HBeAg
   Negative 387 (85.4) 225 (90.4) 1
   Positive   66 (14.6) 24 (9.6) 0.63 (0.38-1.03)
Anti-HCV
   Negative 382 (84.3) 187 (75.1) 1 1    0.300
   Positive   71 (15.7)   62 (24.9) 1.78 (1.22-2.62) 1.23 (0.84-1.80)
HCV-RNA
   Negative 382 (86.2) 187 (77.3) 1 1    0.200
   Positive   61 (13.8)   55 (22.7) 1.84 (1.23-2.76) 1.44 (0.65-1.72)
Anti-HDV
   Negative 410 (90.5) 207 (83.1) 1 1 < 0.001
   Positive 43 (9.5)   42 (16.9) 1.94 (1.23-3.06) 2.68 (1.56-4.61) 
Anti-HIV
   Negative 449 (99.1) 241 (96.8) 1 1    0.010
   Positive   4 (0.9)   8 (3.2) 3.73 (1.11-12.50) 5.78 (1.50-22.27)
Alcohol (drinks/d)
   0 247 (54.5) 117 (47.0) 1 1
   < 4 143 (31.6)   56 (22.4) 0.83 (0.57-1.21) 0.69 (0.48-1.07)    0.080
   4-8 35 (7.7)   37 (14.9) 2.23 (1.34-3.72) 2.30 (1.29-4.01)    0.005
   > 8 28 (6.2)   39 (15.7) 2.94 (1.73-5.01) 2.42 (1.31-4.46)    0.005
BMI (kg/m2)
   < 25 247 (54.5) 121 (48.6) 1
   25-30 173 (38.2) 107 (43.0) 1.26 (0.91-1.75)
   > 30 33 (7.3) 21 (8.4) 1.30 (0.72-2.34)
Crude and adjusted odds ratios (OR) deriving from multiple logistic regression analysis. Patients with HCC were excluded from 
the analysis. HCC: Hepatocellular carcinoma; HDV: Hepatitis D virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency 
virus; BMI: Body mass index.
Table 3  Percentages of cases in different child-pugh classes in 229 of the 249 patients with liver cirrhosis, by aetiology  n  (%)
Child-pugh 
class
CF group 
(n  = 104)
HBV/alcohol group 
(n  = 43)
HBV/HDV group 
(n  = 19)
HBV/HCV group 
(n  = 30)
HBV/ two or more 
cofactors group (n  = 33)
A 71 (68.3) 24 (55.8) 13 (68.4) 17 (56.7)  8 (24.2)
B + C  33 (31.7)b 19 (44.2) 6 (31.6) 13 (43.3) 25 (75.8)b
bP < 0.001 vs hepatitis B virus (HBV)/two or more cofactors. Patients with hepatocellular carcinoma are not included. CF: Cofactor-free; HCV: 
Hepatitis C virus; HDV: Hepatitis D virus.
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